
Vancouver Coworking and Event Space And-Co Achieves Canada's First WELL Coworking Rating
The WELL Coworking Rating is derived from the International WELL Building Institute (IWBI)'s health strategies and integrated with The Instant Group 's platform to help occupiers searching for workspace and all those that enter the space know that the leadership benchmark for health and wellness has been met. In April 2024, IWBI and Instant announced a strategic partnership to spur health and well-being practices in coworking and flexible workspaces. This has culminated in the launch of the first-of-its-kind healthy buildings rating for coworking operators.
The WELL Coworking Rating integrates into The Instant Group's platform, which is the world's largest marketplace for flexible workspace offerings and used by more than 26,000 flex operators, landlords and investors. Prospective coworking and flexible workspace users can search for health and well-being focused workspace using the new feature as they access more than 350,000 flexible workplaces on Instant's digital platforms.
'And-Co is a place built for professionals and designed to bring people together,' said Ryan Dass, Director at And-Co. 'We're giving our community the keys to thrive—with a dedicated on-site team, thoughtful design, and spaces that spark real connection. The WELL Coworking Rating embodies everything we stand for, and we're proud to be the first in Canada to earn it. It proves our commitment to well-being is tangible—and built into everything we do.'
'Canada continues to lead the way in creating healthier, more sustainable workspaces, and And-Co's achievement of the first WELL Coworking Rating in Canada is a proud example of this,' said Olesy Alekseev, vice president and Canada country lead at IWBI. 'This milestone not only builds on the building's existing WELL Core Platinum Certification but also demonstrates how And-Co's flexible working and event space goes above and beyond to meet the specific needs of coworking environments. It highlights how flexible workspaces can be designed to support well-being, setting a new standard for the industry in Vancouver and beyond.'
Sam Pickering, Executive Director, Head of Sustainability at The Instant Group said: 'It is kudos to And-Co for committing to early adoption and setting out to achieve the WELL Coworking Rating, which is derived from health strategies in the WELL Building Standard. The process evaluates nearly 50 different features spanning 10 WELL concepts, from air and water quality to light and thermal comfort, and movement and nourishment. It was a pleasure to work with And-Co and their commitment sets them apart as a leader in healthy flexible workspace.'
Aligned with the growing demand for healthier places and spaces, research shows evidence-based health interventions in buildings help support workplace satisfaction, comfort and productivity, while also helping organizations better attract and retain talent. A 2022 study found that WELL Certified offices increase overall employee satisfaction by 28% and support a 10-point jump in median productivity. In addition, evidence behind the business case for healthy buildings shows that investing in people helps drive several economic benefits, including over seven percent higher rents per-square-foot in certified healthy buildings, longer lease terms, and eight percent increase in employee performance due to improved air quality.
###
About And-CoBuilt for Professionals, Designed for Connection.
And-Co is a purpose-driven workspace and event hub in Vancouver's Coal Harbour, created for professionals who expect more from where they work. With flexible private offices, shared workspaces, and beautifully designed event spaces, And-Co offers an environment where people can perform at their best—while feeling part of something bigger.
It's home to a growing, engaged community, connected through regular member events, arts and culture programming, and initiatives that champion collaboration and solidarity. Wellness is built into every detail—from natural light and movement areas to the support of a dedicated on-site team—delivering a truly human-first experience.
Recognized as Canada's first WELL Rated flexible workspace, And-Co proves that putting people first isn't just a value—it's how we operate every day.
About the International WELL Building Institute
The International WELL Building Institute (IWBI) is a public benefit corporation and the global authority for transforming health and well-being in buildings, organizations and communities. In pursuit of its public-health mission, IWBI mobilizes its community through the development and administration of the WELL Building Standard (WELL), WELL for residential, WELL Community Standard, its WELL ratings and management of the WELL AP credential. IWBI also translates research into practice, develops educational resources and advocates for policies that promote people-first places for everyone, everywhere. IWBI is a participant of the United Nations Global Compact, the world's largest corporate citizenship initiative, and helps companies advance the UN Sustainable Development Goals (SDGs) through the use of WELL. More information on WELL can be found here.
International WELL Building Institute, IWBI, the WELL Building Standard, WELL v2, WELL Certified, WELL AP, WELL EP, WELL Score, The WELL Conference, We Are WELL, the WELL Community Standard, WELL Health-Safety Rated, WELL Performance Rated, WELL Equity Rated, WELL Equity, WELL Coworking Rated, WELL Residence, Works with WELL, WELL and others, and their related logos are trademarks or certification marks of International WELL Building Institute pbc in the United States and other countries.
About The Instant Group
The Instant Group has been rethinking workspace since 1999 with over 500 experts working globally across more than 175 countries. Instant's digital platforms constitute the world's largest digital marketplace for flexible workspace listing meeting rooms, virtual offices, flexible office space and coworking memberships. Its global team advises on commercial real estate solutions from serviced offices to fully customised managed offices, and consulting services for portfolio and net zero strategies. Instant's approach enables agility, hybrid working solutions and improved operational resilience for more than 250,000 businesses every year. Clients include Prudential, Booking.com, Shell, Jaguar Land Rover and GSK. Instant has global offices including London, New York, Mexico City, Hong Kong, Singapore and Sydney. www.theinstantgroup.com www.instantoffices.com
Visit 3BL Media to see more multimedia and stories from International WELL Building Institute (IWBI)
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Gwich'in Tribal Council appoints new interim CEO
The Gwich'in Tribal Council has appointed a new interim chief executive officer to help advise the grand chief and oversee the organization's programs. Brenda McDonald replaces Mark Ellwood as CEO. In a statement Sunday, the Gwich'in Tribal Council announced her appointment, writing that McDonald brings more than two decades of experience working in senior leadership with Indigenous governments, and territorial and federal agencies. The statement says McDonald has managed multi-million dollar budgets, led diverse teams and delivered programs that strengthen local economies and support community priorities. Previous CEO, Ellwood, took over after the board moved to dismiss Jamie Koe earlier this year. McDonald began working as CEO immediately.
Yahoo
13 minutes ago
- Yahoo
Xenon Reports Second Quarter 2025 Financial Results & Business Update
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026– Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED in BPD recently initiated– Phase 1 healthy volunteer study initiated for lead Nav1.7 development candidate for pain– Darren Cline appointed as Chief Commercial Officer to lead commercial build and anticipated azetukalner launch– Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. 'The completion of patient recruitment for our Phase 3 X-TOLE2 study is a significant milestone in the development of azetukalner and keeps us on track to report topline results in early 2026 in anticipation of our first potential approval and commercial product as a company. We remain highly encouraged by the potential value proposition of azetukalner as a novel, next-generation treatment option for people living with the debilitating effects of uncontrolled seizures,' said Ian Mortimer, President and Chief Executive Officer of Xenon. 'In addition, we remain excited about azetukalner's potential beyond epilepsy, with Phase 3 programs underway across multiple neuropsychiatric indications, with the initiation of our Phase 3 X-CEED study in bipolar depression, alongside two clinical studies now underway in our ongoing Phase 3 X-NOVA program in major depressive disorder.' 'We also continue to make significant progress within our early-stage portfolio, advancing multiple drug candidates targeting promising sodium and potassium channel targets, and we are currently conducting two first-in-human studies within our Kv7 and Nav1.7 programs. As we enter this catalyst-rich period, we remain focused on advancing and delivering innovative therapeutics to patients living with epilepsy, depression, and pain.' continued Mr. Mortimer. Business Highlights and Anticipated Milestones Azetukalner Clinical Development Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD) and bipolar depression (BPD). Epilepsy Programs Phase 3 X-TOLE2 clinical study of azetukalner in FOS has now completed patient recruitment, with topline data anticipated in early 2026. Phase 3 X-TOLE3 clinical study of azetukalner in FOS continues to enroll patients and is intended to support potential regulatory submissions in ex-U.S. jurisdictions. Phase 3 X-ACKT clinical study of azetukalner in PGTCS continues to enroll patients and is intended to support regulatory submissions for an additional epilepsy indication. The Company had four abstracts accepted to present at the 36th International Epilepsy Congress (IEC) taking place August 30 to September 3, 2025 in Lisbon, Portugal. Neuropsychiatric Programs X-NOVA2 and X-NOVA3, the first two of three planned Phase 3 clinical trials evaluating azetukalner in patients with MDD, are now underway and screening patients. X-CEED, the first of two planned Phase 3 clinical studies evaluating azetukalner in patients with BPD I and BPD II depression, has been initiated. Early-Stage Pipeline: Next-Generation Ion Channel Modulators Xenon continues to expand its portfolio by leveraging its extensive expertise to discover and develop potassium and sodium channel therapeutics, with the goal of filing multiple INDs, or equivalent, in 2025. Phase 1 study in healthy adult participants is underway for XEN1120, a Kv7 channel opener in development for pain. Work remains ongoing with additional Kv7 development molecules and chemistries with the hypothesis that Kv7 may have utility in a broad range of therapeutic indications including seizure disorders, pain, and neuropsychiatric disorders, such as MDD and BPD. Phase 1 study was initiated for XEN1701, the Company's lead Nav1.7 development candidate for pain. IND-enabling work remains ongoing for additional Nav1.7 candidates. Nav1.7 is an important pain-related target, based on strong human genetic validation, which may represent a new class of medicines without the limitations of opioids. Nav1.1 lead candidate is expected to enter IND-enabling studies in 2025, with pre-clinical data suggesting that targeting Nav1.1 could potentially address the underlying cause and symptoms of Dravet Syndrome. Xenon plans to host multiple R&D webinars with focus on early-stage pipeline programs. The first webinar will take place on October 2, 2025, and focus on our approach to treating pain with drug candidates targeting Nav1.7 and Kv7. Partnered Program As part of Xenon's ongoing collaboration with Neurocrine Biosciences, a Phase 1 study is underway for NBI-921355, an investigational, selective inhibitor of voltage-gated sodium channels Nav1.2 and Nav1.6 in development for the potential treatment of certain types of epilepsy. Corporate The Company appointed Darren Cline to Chief Commercial Officer (CCO). Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage company with the anticipated launch of azetukalner across three potential indications. Second Quarter Financial Results Cash and cash equivalents and marketable securities were $624.8 million as of June 30, 2025, compared to $754.4 million as of December 31, 2024. Based on current operating plans, including the completion of the azetukalner Phase 3 epilepsy studies and supporting late-stage clinical development of azetukalner in MDD and BPD, Xenon anticipates having sufficient cash to fund operations into 2027. As of June 30, 2025, there were 76,939,811 common shares and 2,173,081 pre-funded warrants outstanding. Research and development expenses for the quarter ended June 30, 2025 were $75.0 million, compared to $49.7 million for the same period in 2024. The increase of $25.3 million was primarily attributable to the ongoing azetukalner Phase 3 clinical trials in epilepsy and MDD, as well as start-up costs for the azetukalner Phase 3 BPD clinical trial, and increased personnel-related costs due to an increase in employee headcount. General and administrative expenses for the quarter ended June 30, 2025 were $19.2 million, compared to $19.4 million for the same period in 2024. Other income for the quarter ended June 30, 2025 was $8.9 million, compared to $10.8 million for the same period in 2024. The decrease of $2.0 million was primarily attributable to lower interest income, partially offset by an increase in foreign exchange gain. Net loss for the quarter ended June 30, 2025 was $84.7 million, compared to $57.9 million for the same period in 2024. The increase in net loss was primarily attributable to higher research and development expenses driven by the azetukalner program, increased personnel-related costs, and lower interest income. Conference Call Information Xenon will host a conference call and webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss its second quarter 2025 results. A listen-only webcast can be accessed on the Investors section of the Xenon website, with a replay available following the event. Participants can access the conference call by dialing (800) 715-9871 or (646) 307-1963 for international callers and referencing conference ID 4102397. About Azetukalner Phase 3 Epilepsy Program Xenon's Phase 3 epilepsy program includes three Phase 3 clinical trials in focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS). Designed closely after the Phase 2b X-TOLE clinical trial, the Phase 3 X-TOLE clinical trials are multicenter, randomized, double-blind, placebo-controlled studies evaluating the clinical efficacy, safety, and tolerability of 15 mg or 25 mg of azetukalner administered orally with food as adjunctive treatment in approximately 360 patients with FOS per study. The primary efficacy endpoint is the median percent change (MPC) in monthly seizure frequency from baseline through the 12-week double-blind period (DBP) of azetukalner compared to placebo. X-ACKT is a multicenter, randomized, double-blind, placebo-controlled study evaluating the clinical efficacy, safety, and tolerability of 25 mg of azetukalner administered with food as adjunctive treatment in approximately 160 patients with PGTCS. The primary efficacy endpoint is the MPC in monthly PGTCS frequency from baseline through the 12-week DBP of azetukalner compared to placebo. Upon completion of the DBP in the Phase 3 epilepsy studies, eligible patients may enter an OLE study for up to three years. About Azetukalner Phase 3 MDD X-NOVA Program Xenon's Phase 3 MDD program includes three multicenter, randomized, double-blind, placebo-controlled clinical trials to evaluate the clinical efficacy, safety, and tolerability of 20 mg of azetukalner administered orally with food over the 6-week double-blind period (DBP) as monotherapy treatment in approximately 450 patients with moderate-to-severe major depressive disorder (MDD) per study. The primary efficacy endpoint is the change from baseline in the HAM-D17 score at week 6 in patients who received azetukalner compared to placebo. Upon completion of the DBP, eligible patients may enter an open-label extension (OLE) study for up to 12 months. About Azetukalner Phase 3 BPD X-CEED Program Xenon's Phase 3 BPD program includes two multicenter, randomized, double-blind, placebo-controlled clinical trials to evaluate the clinical efficacy, safety, and tolerability of 20 mg of azetukalner administered orally with food over the 6-week double-blind period (DBP) as monotherapy treatment in approximately 400 patients per study with bipolar depression (BPD) I or II. The primary efficacy endpoint is the change from baseline in the MADRS score at week 6 in patients who received azetukalner compared to placebo. Upon completion of the DBP, eligible patients may enter an OLE study for up to 12 months. About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon's lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including Kv7 and Nav1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit and follow us on LinkedIn and X. Safe Harbor Statement This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. These forward-looking statements are not based on historical fact, and include statements regarding the timing of and potential results from clinical trials; the potential efficacy, safety profile, future development plans in current and anticipated indications, addressable market, regulatory success and commercial potential of our and our partners' product candidates; the efficacy of our clinical trial designs; our ability to successfully develop and achieve milestones in our azetukalner and other pipeline and development programs, including the anticipated filing of INDs and NDAs; the timing and results of our interactions with regulators; our ability to successfully develop and obtain regulatory approval of azetukalner and our other product candidates; and anticipated timing of topline data readout from our clinical trials of azetukalner. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: clinical trials may not demonstrate safety and efficacy of any of our or our collaborators' product candidates; promising results from pre-clinical development activities or early clinical trial results may not be replicated in later clinical trials; our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations may be incorrect; our ongoing discovery and pre-clinical efforts may not yield additional product candidates; any of our or our collaborators' product candidates, including azetukalner, may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; regulatory agencies may impose additional requirements or delay the initiation or completion of clinical trials; the impact of market, industry, and regulatory conditions on clinical trial enrollment; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; the impact of unstable economic conditions in the general domestic and global economic markets; adverse conditions from geopolitical events; as well as the other risks identified in our filings with the U.S. Securities and Exchange Commission and the securities commissions in British Columbia, Alberta, and Ontario. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. 'Xenon' and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner. Contacts: For Investors:Chad Fugere Vice President, Investor Relations(857) 675-7275investors@ For Media:Colleen AlabisoSenior Vice President, Corporate Affairs(617) 671-9238media@ XENON PHARMACEUTICALS Consolidated Balance Sheets(Expressed in thousands of U.S. dollars) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents and marketable securities $ 487,545 $ 626,905 Other current assets 12,707 8,359 Marketable securities, long-term 137,297 127,496 Other long-term assets 36,732 35,379 Total assets $ 674,281 $ 798,139 Liabilities Current liabilities: Accounts payable and accrued liabilities $ 31,588 $ 34,221 Other current liabilities 1,459 1,369 Other long-term liabilities 7,256 7,646 Total liabilities $ 40,303 $ 43,236 Shareholders' equity $ 633,978 $ 754,903 Total liabilities and shareholders' equity $ 674,281 $ 798,139XENON PHARMACEUTICALS Consolidated Statements of Operations and Comprehensive Loss(Expressed in thousands of U.S. dollars except share and per share amounts) Three Months EndedJune 30, Six Months EndedJune 30, 2025 2024 2025 2024 Revenue $ — $ — $ 7,500 $ — Operating expenses: Research and development 74,985 49,702 136,185 93,952 General and administrative 19,244 19,402 38,282 34,193 Total operating expenses 94,229 69,104 174,467 128,145 Loss from operations (94,229 ) (69,104 ) (166,967 ) (128,145 ) Other income 8,897 10,847 17,015 22,369 Loss before income taxes (85,332 ) (58,257 ) (149,952 ) (105,776 ) Income tax recovery (expense) 626 333 199 (79 ) Net loss $ (84,706 ) $ (57,924 ) $ (149,753 ) $ (105,855 ) Other comprehensive income (loss): Unrealized gain (loss) on available-for-sale securities 949 (443 ) 1,725 (2,135 ) Comprehensive loss $ (83,757 ) $ (58,367 ) $ (148,028 ) $ (107,990 ) Net loss per common share: Basic and diluted $ 1.07 $ (0.75 ) $ 1.90 $ (1.36 ) Weighted average common shares outstanding: Basic and diluted 78,953,445 77,671,128 78,820,474 77,632,864 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
43 minutes ago
- Yahoo
Pixalate's July 2025 Canada Publisher Rankings for Websites, Mobile and CTV Apps: ‘TextNow: Call + Text Unlimited', ‘bbc.com', and ‘The Roku Channel' Among Top-Ranked for Open Programmatic Ad Traffic Quality
According to Pixalate's July 2025 rankings, 'Vita MahJong' (Apple App Store) and 'TextNow: Call + Text Unlimited' (Google Play Store) ranked No. 1 among mobile apps; 'Pluto TV' (Amazon Fire TV), 'The Roku Channel' (Roku), 'Xumo Play' (Samsung Smart TV), and 'Fubo: Watch Live TV & Sports' (Apple TV) were top-ranked CTV apps; ranked as No. 1 website for programmatic ad quality in Canada London, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Pixalate, the leading ad fraud protection, privacy, and compliance analytics platform, has released the July 2025 Publisher Trust Index (PTI) for Canada. This index evaluates websites, mobile apps across the Apple App Store, Google Play Store, and Connected TV (CTV) apps on Roku, Amazon Fire TV, Apple TV, and Samsung Smart TV. The Publisher Trust Indexes represent a comprehensive approach to quality measurement and provide monthly rankings of the world's websites and apps, offering unprecedented transparency to the open programmatic advertising ecosystem. In addition to the report for Canada, Pixalate has also released Publisher Trust Indexes for Brazil, the United States (U.S.), the United Kingdom (UK), Germany, Spain, the Netherlands, and Japan. Canada Web PTI Rankings (July 2025) Canada Mobile PTI Rankings (July 2025) Apple App Store Vita MahJong Solitaire by Mobility Ware Bus Escape: Traffic Jam Google Play Store TextNow: Call + Text Unlimited Kijiji: Buy and sell local Hit & Run: Solo Leveling Canada Connected TV PTI Rankings (July 2025)Roku The Roku Channel - Food Recipes and Cooking Shows Tubi Samsung Smart TV Xumo Play Fubo: Watch Live Bloomberg Amazon Fire TV Pluto TV Lifetime Fubo: Watch Live TV & Sports Apple TV Fubo: Watch Live TV & Sports Food Network GO - Live TV Bloomberg Business News Daily Pixalate's data science team analyzed over 34 billion global open programmatic ad impressions across 15+ million Google Play Store and Apple App Store mobile apps, and Connected TV (CTV) apps across Roku, Amazon Fire TV, Samsung Smart TV, and Apple TV app stores in July 2025 to compile the global Publisher Trust Indexes. Pixalate uses its proprietary algorithms to measure quality metrics, including invalid traffic (IVT or ad fraud), Made For Advertising (MFA) risk, brand safety, ad density, viewability, reach, and more. The Publisher Trust Index spans rankings for 235+ countries across all four global regions: North America, EMEA, APAC, and LATAM, and provides breakdowns by 20+ different IAB taxonomy website categories. Pixalate's methodology can be found at Publisher Trust Index: Methodology. Download the Publisher Trust Index Reports Netherlands Canada Brazil U.S. UK Germany Spain Japan About Pixalate Pixalate is a global platform specializing in privacy compliance, ad fraud prevention, and digital ad supply chain data intelligence. Founded in 2012, Pixalate is trusted by regulators, data researchers, advertisers, publishers, ad tech platforms, and financial analysts across the Connected TV (CTV), mobile app, and website ecosystems. Pixalate is accredited by the MRC for the detection and filtration of Sophisticated Invalid Traffic (SIVT). July 2025 Canada Publisher Trust Index (PTI) reflects Pixalate's opinions with respect to factors that Pixalate believes may be useful to the digital media industry. Our reports and indexes examine programmatic advertising activity on mobile apps, website domains and Connected TV (CTV) apps. Any insights shared are grounded in Pixalate's proprietary technology and analytics, which Pixalate is continuously evaluating and updating. Any references to outside sources in the Indexes and herein should not be construed as endorsements. Pixalate's opinions are just that, opinions, which means that they are neither facts nor guarantees. This report is not intended to impugn the standing or reputation of any person, entity or app but, instead, to report findings and trends pertaining to the time period studied. Per the MRC, ''Fraud' is not intended to represent fraud as defined in various laws, statutes and ordinances or as conventionally used in U.S. Courts or other legal proceedings, but rather a custom definition strictly for advertising measurement purposes. Also per the MRC, ''Invalid Traffic' is defined generally as traffic that does not meet certain ad serving quality or completeness criteria, or otherwise does not represent legitimate ad traffic that should be included in measurement counts. Among the reasons why ad traffic July be deemed invalid is it is a result of non-human traffic (spiders, bots, etc.), or activity designed to produce fraudulent traffic.'CONTACT: Nina Talcott ntalcott@